Alzinova (ALZ) Q3 2025 earnings summary

Executive summary

• Achieved FDA approval for IND application and Fast Track designation for ALZ-101, advancing to Phase II clinical trials in the US for Alzheimer's disease.

• Secured SEK 11 million in short-term financing to support operations into Q1 2026 and maintain momentum for clinical development.

• Completed Phase 1b study for ALZ-101, meeting safety, tolerability, and immunogenicity endpoints, with positive trends in efficacy and biomarker response.

• Strengthened partnerships and investor dialogue, with increased interest from international pharmaceutical companies and participation in major industry events.

Financial highlights

• Q3 2025 loss after financial items: SEK -6,960 thousand (Q3 2024: -4,152 thousand).

• Cash flow for Q3 2025: SEK -11,025 thousand (Q3 2024: 22,687 thousand).

• Cash and cash equivalents at period end: SEK 485 thousand (Q3 2024: 27,674 thousand).

• Nine-month loss after financial items: SEK -20,375 thousand (2024: -13,988 thousand).

• Equity at period end: SEK 127,852 thousand (Q3 2024: 130,385 thousand); equity ratio 93.4%.

Outlook and guidance

• Focus on initiating Phase II study for ALZ-101 once long-term financing is secured.

• Continued efforts to establish strategic partnerships and secure additional funding.

• Ongoing preparations for clinical development of ALZ-201 antibody.